argenx just committed up to $1.15bn to a biotech with no disclosed clinical drug. What is it really buying?
argenx will pay $550 million upfront to acquire Unnatural Products in a deal worth up to $1.15 billion, adding oral peptide discovery.
Pharma & Biotech
Pharma & Biotech
argenx halts Phase 3 efgartigimod Sjögren’s trial after futility analysis
argenx stops the Phase 3 UNITY efgartigimod trial in Sjögren’s disease for futility despite earlier positive Phase 2 results.
Features & Analysis
Why destroying IgG faster can treat myasthenia gravis without depleting B cells
FcRn normally rescues IgG antibodies from intracellular destruction and returns them to circulation. Blocking that recycling pathway accelerates IgG clearance, including pathogenic autoantibodies, without directly eliminating the B cells that produced them.
Pharma & Biotech
argenx Forte Biosciences acquisition: What the $2.2bn FB102 deal means for immunology
argenx is buying Forte Biosciences for $2.2bn to secure FB102. See why early vitiligo and celiac data make Phase 2 execution decisive.
Pharma & Biotech
Zai Lab’s August 6 earnings could reveal whether its 2026 commercial reset is starting to work
Zai Lab reports Q2 2026 results on August 6 as investors assess revenue pressure, COBENFY and TIVDAK launches, and zoci pipeline progress.
Pharma & Biotech
Why Argenx’s broader Vyvgart label changes the treatment equation in generalized myasthenia gravis
Vyvgart now covers all adult gMG serotypes. Argenx gains a wider label, but payers and real-world durability remain the next test.